ATA11842004A - Impfstoff gegen die alzheimer-krankheit - Google Patents

Impfstoff gegen die alzheimer-krankheit

Info

Publication number
ATA11842004A
ATA11842004A AT0118404A AT11842004A ATA11842004A AT A11842004 A ATA11842004 A AT A11842004A AT 0118404 A AT0118404 A AT 0118404A AT 11842004 A AT11842004 A AT 11842004A AT A11842004 A ATA11842004 A AT A11842004A
Authority
AT
Austria
Prior art keywords
alzheimer disease
vaccine against
vaccine
alzheimer
disease
Prior art date
Application number
AT0118404A
Other languages
English (en)
Other versions
AT413946B (de
Original Assignee
Mattner Frank Dr
Schmidt Walter Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mattner Frank Dr, Schmidt Walter Dr filed Critical Mattner Frank Dr
Priority to AT0118404A priority Critical patent/AT413946B/de
Priority to TW094120197A priority patent/TWI353848B/zh
Priority to JP2007520814A priority patent/JP5179866B2/ja
Priority to EP05769807A priority patent/EP1765390A2/de
Priority to US11/630,679 priority patent/US8022180B2/en
Priority to CA002573424A priority patent/CA2573424A1/en
Priority to AU2005261688A priority patent/AU2005261688B2/en
Priority to CN2012105573960A priority patent/CN103263664A/zh
Priority to PCT/EP2005/053225 priority patent/WO2006005707A2/en
Priority to KR1020077002209A priority patent/KR101228409B1/ko
Priority to CNA2005800306410A priority patent/CN101043901A/zh
Publication of ATA11842004A publication Critical patent/ATA11842004A/de
Application granted granted Critical
Publication of AT413946B publication Critical patent/AT413946B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0118404A 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit AT413946B (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AT0118404A AT413946B (de) 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit
TW094120197A TWI353848B (en) 2004-07-13 2005-06-17 Mimotope peptide,composition,and immunogenic compo
EP05769807A EP1765390A2 (de) 2004-07-13 2005-07-06 Verfahren zur vorbeugung und behandlung der alzheimer-krankheit
US11/630,679 US8022180B2 (en) 2004-07-13 2005-07-06 Method for preventing and treating Alzheimer's disease
JP2007520814A JP5179866B2 (ja) 2004-07-13 2005-07-06 アルツハイマー病の予防および治療方法
CA002573424A CA2573424A1 (en) 2004-07-13 2005-07-06 Method for preventing and treating alzheimer´s disease
AU2005261688A AU2005261688B2 (en) 2004-07-13 2005-07-06 Method for preventing and treating Alzheimer´s disease
CN2012105573960A CN103263664A (zh) 2004-07-13 2005-07-06 预防和治疗阿尔茨海默病的方法
PCT/EP2005/053225 WO2006005707A2 (en) 2004-07-13 2005-07-06 Method for preventing and treating alzheimer´s disease
KR1020077002209A KR101228409B1 (ko) 2004-07-13 2005-07-06 알츠하이머 질환의 예방 및 치료 방법
CNA2005800306410A CN101043901A (zh) 2004-07-13 2005-07-06 预防和治疗阿尔茨海默病的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0118404A AT413946B (de) 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit

Publications (2)

Publication Number Publication Date
ATA11842004A true ATA11842004A (de) 2005-11-15
AT413946B AT413946B (de) 2006-07-15

Family

ID=35406000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0118404A AT413946B (de) 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit

Country Status (10)

Country Link
US (1) US8022180B2 (de)
EP (1) EP1765390A2 (de)
JP (1) JP5179866B2 (de)
KR (1) KR101228409B1 (de)
CN (2) CN101043901A (de)
AT (1) AT413946B (de)
AU (1) AU2005261688B2 (de)
CA (1) CA2573424A1 (de)
TW (1) TWI353848B (de)
WO (1) WO2006005707A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010435A1 (en) 2002-12-19 2007-01-11 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
KR100820164B1 (ko) 2007-03-31 2008-04-08 한국전기연구원 피부질환 치료용 레이저 장치
KR100815483B1 (ko) 2007-05-09 2008-03-20 한국전기연구원 비등방성 레이저 결정을 이용한 다이오드 펌핑된 레이저장치
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009054537A1 (ja) * 2007-10-25 2009-04-30 Kagoshima University アミロイドβペプチドのミミック分子を用いたペプチドワクチン
WO2009149487A2 (en) * 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
AT509611B1 (de) * 2008-06-12 2012-04-15 Affiris Forschungs-Und Entwicklungs Gmbh Vakzin
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
WO2011106732A1 (en) 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
KR101849975B1 (ko) * 2011-01-17 2018-05-31 삼성전자주식회사 음극, 음극 활물질, 음극의 제조방법 및 이를 채용한 리튬 전지
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
ES2496341T3 (es) 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
KR20140068105A (ko) * 2011-12-29 2014-06-05 타오 헬스 라이프 파마 가부시키가이샤 아밀로스페로이드가 결합하여 성숙 신경 세포사를 유발하는 표적 분자, 아밀로스페로이드가 유도하는 신경 세포사를 억제하는 방법 및 물질, 및 그들의 이용
EP2659908A1 (de) * 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
EP2787347A1 (de) 2013-04-03 2014-10-08 Affiris AG Verfahren zur Erkennung von Aß-spezifischen Antikörpern in einer biologischen Probe
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
CA2946931A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165964A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
KR102857456B1 (ko) 2015-11-03 2025-09-08 에이씨 이뮨 에스에이 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법
EP3658172A4 (de) 2017-07-25 2021-05-05 TrueBinding, Inc. Behandlung von krebs durch blockierung der interaktion von tim-3 und seinem liganden
KR102852206B1 (ko) 2019-01-14 2025-09-02 필립모리스 프로덕츠 에스.에이. 건조 분말 흡입기 장치
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508685D0 (en) * 1985-04-03 1985-05-09 Minor P D Peptides
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
ES2344189T3 (es) * 1999-09-03 2010-08-20 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer.
WO2001049721A2 (en) * 1999-12-30 2001-07-12 Bristol-Myers Squibb Company Bacterial genes and proteins that are essential for cell viability and their uses
ES2279869T3 (es) * 2001-06-20 2007-09-01 Ramot At Tel Aviv University Ltd. Peptido antigenico comprendido por mulitples copias de un epitope de un polipeptido implicado en enfermedades de formacion de placas y los procedimientos de uso correspondientes.
EA007452B1 (ru) 2002-04-12 2006-10-27 Пи Джи Рисерч Фаундейшн, Инк. Многоколоночный генератор с инверсией избирательности для производства сверхчистых радионуклидов
JP2004016282A (ja) 2002-06-12 2004-01-22 Olympus Corp 内視鏡用画像処理装置
DE60336902D1 (de) * 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
EP1523499A2 (de) 2002-07-24 2005-04-20 Innogenetics N.V. Fragmente von beta-amyloid als angriffspunkt einer impfung gegen alzheimersche krankheit
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit

Also Published As

Publication number Publication date
US8022180B2 (en) 2011-09-20
CN103263664A (zh) 2013-08-28
WO2006005707A2 (en) 2006-01-19
KR101228409B1 (ko) 2013-01-31
JP5179866B2 (ja) 2013-04-10
AU2005261688A1 (en) 2006-01-19
CA2573424A1 (en) 2006-01-19
US20090004210A1 (en) 2009-01-01
AU2005261688B2 (en) 2010-11-11
CN101043901A (zh) 2007-09-26
TWI353848B (en) 2011-12-11
TW200602071A (en) 2006-01-16
WO2006005707A3 (en) 2006-08-17
AT413946B (de) 2006-07-15
EP1765390A2 (de) 2007-03-28
JP2008506666A (ja) 2008-03-06
KR20070032033A (ko) 2007-03-20

Similar Documents

Publication Publication Date Title
DK1968631T3 (da) Vaccine
DE502004003234D1 (de) Gegen missbrauch gesicherte darreichungsform
DE502004004205D1 (de) Gegen missbrauch gesicherte darreichungsform
NO20054608D0 (no) Influensavirusvaksine
DK1957528T3 (da) Nukleotid-vaccine
ATE515515T1 (de) Immunglobuline gegen menschlisches osm
DE602005010597D1 (de) Bildaufzeichnungsverfahren
ATE432082T1 (de) Impfstoff gegen periodontale krankheit
ATE506362T1 (de) 1-aza-bicycloä3.3.1ünonane
DK1957073T3 (da) Lægemiddel
NL1031626A1 (nl) Verbindingen die bruikbaar zijn in therapie.
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
IS8325A (is) Bóluefni
EP1948782A4 (de) Impfstoffadjuvantien
DE602005003524D1 (de) Biegevorrichtung
DK1660123T3 (da) Rotavirusvaccine
DE602005024139D1 (de) Die anzeigevorrichtung
DK1877549T3 (da) HIV-vaccine
DE602006014799D1 (de) Heilmittel gegen sensorische erkrankungen
ES1058102Y (es) Lentilla terapeutica.
ES2365717T5 (es) Vacunacion meningococica conjugada.
DK1960510T3 (da) Ammoniakspecifik 5'-xmp-aminasemutant
FI6726U1 (fi) Hieromalaite
DE602005000531D1 (de) Formgesenk
ITCR20050007U1 (it) Piegaprofili "stefiglass"

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
MM01 Lapse because of not paying annual fees

Effective date: 20151115